Entrepreneurs Fund

Entrepreneurs Fund provides early stage and growth financing alongside active support to entrepreneurial teams. Their current areas of investment focus are Life-sciences, Water, Materials and Automotive Technology.

Maciek Drozdz

Investment Manager

Alexander Hardtmuth

Investment Manager

44 past transactions

General Fusion

Series E in 2019
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Realeyes

Series B in 2019
Realeyes specializes in computer vision and emotion AI, providing a platform that measures customer attention and emotional responses through facial recognition technology. By utilizing webcams and machine-learning methods, the company quantifies emotional reactions as viewers engage with video content online. This capability enables over 200 prominent brands and media companies, including Mars Inc., P&G, Expedia, TikTok, Google, Netflix, Warner Media, and Teads, to optimize their content and enhance customer experiences. Realeyes empowers clients to effectively target their audiences by delivering insights that drive growth and improve engagement.

OptiNose

Series D in 2017
OptiNose is a specialty pharmaceutical company dedicated to developing and commercializing nasal drug delivery technologies and combination drug/device therapies. The company’s proprietary Bi-Directional Delivery system enhances the efficiency of drug administration to the nasal cavity, ensuring that a significant portion of the medication is deposited in the upper posterior regions, rather than the lungs. This innovative approach has been shown to provide a faster onset of action, greater therapeutic effects with lower doses, and reduced side effects in clinical trials. One of its key products, XHANCE, is a nasal spray containing fluticasone propionate, specifically designed to treat chronic rhinosinusitis with nasal polyps by delivering medication directly to the site of inflammation. OptiNose operates offices in Norway and the UK, focusing on patients supported by ear, nose, and throat specialists, as well as allergy professionals.

Vasopharm

Venture Round in 2016
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.

Sequana Medical

Series C in 2015
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

General Fusion

Venture Round in 2015
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

D3O

Venture Round in 2015
D3O is an innovative company specializing in impact protection solutions through the development of patented smart materials. Its technology, based on non-Newtonian fluids, produces shock-absorbing materials utilized across various sectors, including motorcycle, sports, footwear, electronics, military, and workwear. D3O® gained recognition during the 2006 Winter Olympics when it was adopted by the US and Canadian ski teams for its advanced soft armor. The company's products are characterized by their lightweight, flexible, and breathable design, providing effective protection without compromising comfort. D3O continues to lead the market in impact protection and shock absorption, offering pioneering solutions that enhance safety for soldiers, professional athletes, and industrial workers alike.

Exosect

Venture Round in 2015
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

Rakuten Fits Me

Venture Round in 2014
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it. Each shopper’s measurements are calculated based on height, weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements. Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper. Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences. Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time.

SmartKem

Series A in 2014
SmartKem Limited is a Manchester-based company that develops and markets organic semiconductors for various display technologies, including liquid crystal and organic light-emitting diode displays. Established in 2008, the company specializes in the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for use in transistor backplanes. SmartKem's patented TRUFLEX inks enable the production of organic thin-film transistor circuits on low-cost substrates, facilitating applications in mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company generates revenue through the sale of these inks and demonstration products, contributing to the advancement of a new generation of displays and sensors.

OptiNose

Series C in 2014
OptiNose is a specialty pharmaceutical company dedicated to developing and commercializing nasal drug delivery technologies and combination drug/device therapies. The company’s proprietary Bi-Directional Delivery system enhances the efficiency of drug administration to the nasal cavity, ensuring that a significant portion of the medication is deposited in the upper posterior regions, rather than the lungs. This innovative approach has been shown to provide a faster onset of action, greater therapeutic effects with lower doses, and reduced side effects in clinical trials. One of its key products, XHANCE, is a nasal spray containing fluticasone propionate, specifically designed to treat chronic rhinosinusitis with nasal polyps by delivering medication directly to the site of inflammation. OptiNose operates offices in Norway and the UK, focusing on patients supported by ear, nose, and throat specialists, as well as allergy professionals.

Sequana Medical

Series C in 2014
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Xeros

Post in 2014
Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

General Fusion

Series C in 2013
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Vasopharm

Series F in 2013
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.

NewMotion

Series C in 2013
NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy for charging. The company operates one of the largest and fastest-growing charging networks in Europe, with over 12,000 connected charge points. Two out of three electric vehicle drivers in the Netherlands utilize NewMotion's charging solutions. Additionally, NewMotion offers charging points and solutions for businesses, partnering with leasing companies and car manufacturers to enhance the accessibility of charging infrastructure. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, making electric driving more convenient and enjoyable for users.

Exosect

Venture Round in 2013
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

Rakuten Fits Me

Series A in 2013
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it. Each shopper’s measurements are calculated based on height, weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements. Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper. Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences. Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time.

Xeros

Venture Round in 2013
Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

Realeyes

Series A in 2013
Realeyes specializes in computer vision and emotion AI, providing a platform that measures customer attention and emotional responses through facial recognition technology. By utilizing webcams and machine-learning methods, the company quantifies emotional reactions as viewers engage with video content online. This capability enables over 200 prominent brands and media companies, including Mars Inc., P&G, Expedia, TikTok, Google, Netflix, Warner Media, and Teads, to optimize their content and enhance customer experiences. Realeyes empowers clients to effectively target their audiences by delivering insights that drive growth and improve engagement.

Exosect

Venture Round in 2012
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

Prosonix

Series B in 2012
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

Rakuten Fits Me

Venture Round in 2012
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it. Each shopper’s measurements are calculated based on height, weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements. Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper. Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences. Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time.

NewMotion

Series B in 2012
NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers, focusing on facilitating the use of renewable energy for charging. The company operates one of the largest and fastest-growing charging networks in Europe, with over 12,000 connected charge points. Two out of three electric vehicle drivers in the Netherlands utilize NewMotion's charging solutions. Additionally, NewMotion offers charging points and solutions for businesses, partnering with leasing companies and car manufacturers to enhance the accessibility of charging infrastructure. The company is actively expanding its network across the Netherlands, Belgium, Germany, and Norway, making electric driving more convenient and enjoyable for users.

SOASTA

Venture Round in 2011
SOASTA, Inc. is a cloud-based performance analytics platform that specializes in testing and monitoring solutions for digital businesses globally. Established in 2006 and headquartered in Mountain View, California, the company provides a range of products, including mPulse for real user monitoring, CloudTest for load and performance testing, TouchTest for mobile test automation, and the Digital Operations Center for performance visibility. SOASTA's solutions enable businesses to understand the relationship between user behavior, application performance, and business outcomes, offering actionable insights to enhance digital performance in real time. With over 10 million tests conducted and more than 100 billion user experiences measured, SOASTA serves prominent clients such as Experian, Hallmark, and Microsoft. The company also offers comprehensive testing services and training options to support organizations throughout the development and deployment lifecycle. As of 2017, SOASTA operates as a subsidiary of Akamai Technologies, Inc.

Cytoo

Series C in 2011
Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Exosect

Venture Round in 2011
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

Prosonix

Series B in 2011
Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

General Fusion

Series B in 2011
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Sequana Medical

Series B in 2011
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Accept Software

Series C in 2010
Accept helps companies increase the speed and certainty of new product success and turn product innovation into a competitive advantage. Accept SaaS innovation management solutions help companies engage communities, prioritize and manage new ideas, align products with company strategy, and unify execution across teams.

Xeros

Venture Round in 2010
Xeros Technology Group plc specializes in developing and commercializing polymer-based technologies aimed at reducing water usage in cleaning processes across various sectors, including fabric and garment manufacturing, as well as industrial and domestic laundry. The company has created innovative products such as XOrbs, which utilize polymer technology to effectively remove dirt and stains with minimal water, and XDrum, designed for fabric and garment manufacturing applications. Additionally, it offers XFiltra, a system that facilitates the easy disposal of collected fibers by de-watering filtered materials. Originating from research by Professor Stephen Burkinshaw at the University of Leeds, Xeros's patented polymer bead cleaning system demonstrates significant potential for cost savings and environmental benefits in commercial laundry and other industries like leather processing and metal cleaning. Based in Rotherham, United Kingdom, Xeros continues to expand its operations in Europe and North America.

Exosect

Venture Round in 2009
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

Evolva

Post in 2009
Evolva is a biotechnology company based in Reinach, Switzerland, founded in 2004. The company specializes in the research, development, and commercialization of nature-based ingredients that are ready for formulation. Utilizing a proprietary synthetic biology platform, Evolva creates innovative small-molecule compounds that replicate the beneficial properties of natural products while mitigating their disadvantages. Their offerings find applications in various sectors, including flavors and fragrances, health ingredients, and health protection. Through its advanced technology, Evolva aims to provide high-quality ingredients that meet the needs of diverse industries.

General Fusion

Series A in 2009
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.

Inge watertechnologies

Venture Round in 2009
Inge Watertechnologies specializes in the development of ultrafiltration technology for water treatment applications. The company's innovative membrane separation process utilizes ultra-small pore filters that effectively remove particles, suspended solids, and microorganisms, including bacteria and viruses. This technology is designed to ensure smart, safe, and reliable solutions for treating various types of water, including drinking water, processed water, seawater, and wastewater. By providing dependable access to clean water, Inge Watertechnologies addresses critical needs in water management and environmental sustainability.

Exosect

Venture Round in 2008
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

VAIREX international

Series A in 2008
VAIREX international limitedis a privately held designer, manufacturer, and supplier of air management systems. These critical and efficient systems, consisting of integrated compressors, motors, and controllers, deliver clean air in hydrogen fuel cell and diesel emissions control devices. VAIREX's customers include leading Tier One suppliers and OEMs to the fuel cell and diesel industries in Europe, Asia, and North America.

Exosect

Venture Round in 2008
Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology and products, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain.

iPolicy Networks

Venture Round in 2006
iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.

t2cure

Series A in 2006
t2cure GmbH is a biopharmaceutical company based in Frankfurt am Main, Germany, focused on developing progenitor cell-based regenerative therapeutics for cardiovascular diseases. Founded in 2006, the company specializes in providing autologous bone marrow-derived progenitor cells as treatments for conditions such as ischemic heart diseases, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy. t2cure's innovative therapeutics aim to enhance recovery by improving blood flow and promoting tissue repair through the release of regenerative messenger substances. By harnessing the potential of mononuclear cells obtained from patients' bone marrow, t2cure seeks to offer new treatment options for individuals suffering from various cardiovascular ailments.

iPolicy Networks

Series B in 2005
iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.